1. Home >
  2. M&A >
  3. Divestiture >
  4. Ireland >
  5. Mandos Acquires Mallinckrodt - Adrabetadex

M&A Deal Summary

Mandos Acquires Mallinckrodt - Adrabetadex

On May 19, 2021, Mandos acquired life science company Mallinckrodt - Adrabetadex from Mallinckrodt

Acquisition Highlights
  • This is Mandos’ 1st transaction in the Life Science sector.
  • This is Mandos’ 1st transaction in Ireland.

M&A Deal Summary
Date 2021-05-19
Target Mallinckrodt - Adrabetadex
Sector Life Science
Buyer(s) Mandos
Sellers(s) Mallinckrodt
Deal Type Divestiture

Target

Mallinckrodt - Adrabetadex

Dublin, Ireland
Mallinckrodt's Adrabetadex is a drug in development for the treatment of Niemann-Pick Type C1 disease (NPC1).

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Mandos

California, United States
Category Company
Sector Healthcare Services
DESCRIPTION

Mandos is a provider of health care services to clients based in the United States.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: Ireland M&A 1 of 1
Year: 2021 M&A 1 of 1

Seller(S) 1

SELLER

Mallinckrodt

Dublin, United Kingdom
Category Company
Founded 1867
Sector Life Science
Employees2,673
Revenue 2.2B USD (2021)
DESCRIPTION

Mallinckrodt is a specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. Mallinckrodt was founded in 1867 and is based in Dublin, Ireland.

DEAL STATS #
Overall 6 of 7
Sector: Life Science M&A 2 of 2
Type: Divestiture M&A Deals 6 of 7
Country: Ireland M&A 4 of 4
Year: 2021 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-18 Silence Therapeutics

London, United Kingdom

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Silence Therapeutics proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Silence Therapeutics was incorporated in 1994 and is based in London, United Kingdom.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-08-05 Therakos

West Chester, Pennsylvania, United States

Therakos is a fully integrated extracorporeal photopheresis (ECP) delivery system for autologous immunomodulatory therapy. Therakos is based in West Chester, Pennsylvania.

Sell $925M
Mergr

Solution for

Product

Company

Legal